BIOA
BioAge Labs, Inc.
$17.99
+0.95%
2026-05-08
About BioAge Labs, Inc.
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Key Fundamentals
P/E Ratio
1.59
Forward P/E
-6.38
EPS (TTM)
$-2.24
ROE
-27.1%
Profit Margin
0.0%
Debt/Equity
2.04
Price/Book
2.43
Market Cap
$785.8M
Avg Volume (10D)
356K
Recent Breakout Signals
No recent breakout signals detected for BIOA.
Recent Price Range (60 Days)
60D High
$23.00
60D Low
$15.47
Avg Volume
499K
Latest Close
$17.99
Get breakout alerts for BIOA
Sign up for Breakout Scanner to receive daily notifications when BIOA triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
BioAge Labs, Inc. (BIOA) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors BIOA daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. BIOA operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry. Data is provided for informational purposes only and does not constitute financial advice.